NCT02434276Unknown2 期
A Phase II, Multicenter, Randomized, Double-Blind, Active Comparator Controlled Study of the Immunogenicity and Safety of VAX2012Q, A Quadrivalent Influenza Vaccine in Healthy Adults 18-64 Years
VaxInnate Corporation7 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2015年5月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 450
- 试验地点
- 7
- 主要终点
- Seroconversion rates to the 4 components of VAX2012Q
研究概览
简要总结
This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.
详细描述
This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either VAX2012Q or Fluzone. Four hundred fifty (450) subjects will be randomized 1:1:1 ratio of either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine.
Randomization will be stratified for age (18-49 and 50-64 years). Subjects will be stratified by two age groups (18-49 and 50-64) and randomized in a 1:1:1 ratio to either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine. 25-35% of the total study population will be recruited into the 50-64 age group.
The primary objective of the study is to evaluate the seroconversion rates at Day 21 for both dose levels of VAX2012Q.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females, 18-64 years of age.
- •Females must be:
- •Surgically sterilized
- •Post menopausal:
- •12 months of spontaneous amenorrhea or
- •6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 milli-International Units (mIU)/ml or
- •6 weeks postsurgical bilateral oophorectomy
- •Those of childbearing potential must have a negative pre-treatment serum pregnancy test followed by a confirmatory urine pregnancy test immediately prior to vaccination and must agree to use a reliable form of contraception for at least 21 days post vaccination including contraceptives, intrauterine device, double-barrier method.
- •In good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator.
- •Must sign informed consent indicating understanding of the purpose of and procedures required for the study and willingness to participate.
排除标准
- •Within 6 months preceding the administration of the study vaccine, receiving any licensed or investigational vaccine.
- •Within 30 days preceding the administration of the study vaccine, receiving any investigational drug.
- •Excessive chronic alcohol use within the last 5 years.
- •History of drug abuse, other than recreational cannabis use, within the last 5 years that could affect the subject's participation in the study.
- •Significant psychiatric illness within the last 12 months which would interfere with the study.
- •A chronic illness that is not medically stable, receiving a concomitant therapy in which the medication dose has not been stable for at least 3 months prior to immunization or has any other condition that could interfere with the study.
- •Clinically significant abnormal liver function tests at screening: alanine transaminase (ALT) or aspartate aminotransferase (AST) >2.5 Upper Limit of Normal (ULN).
- •Total bilirubin > 1.5 ULN if ALT or AST > ULN or total bilirubin > 2 ULN with ALT and AST within normal range .
- •Creatinine >1.7mg/dL, Hemoglobin < 11g/dL for females; <12.5 g/dL for males, white blood cells (WBC) <2500cell/mm3 or > 15,000cell/mm3, Platelet Count <125,000cell/mm3
- •Positive serology for HBSAg, hepatitis C virus (HCV) or HIV
- •Have cancer or have received treatment for cancer within three years, excluding in situ cervical carcinoma or basal /squamous cell carcinoma of the skin at other than the vaccination site.
- •Any autoimmune disease.
- •Presently receiving or having a recent history of receiving (≤ six months) any medication or therapeutic modality that affects the immune system or a drug known to be frequently associated with significant major organ toxicity or system corticosteroids (oral or injectable).
- •History of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component.
- •Allergic to egg or egg products.
- •History of Guillain-Barré Syndrome.
- •Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination
- •Donation of blood or blood products within 4 weeks prior to vaccination or during the 4 week study period following vaccination.
- •Acute disease within 72 hours prior to vaccination.
- •An oral temperature >100.4°F (38°C) on the day of vaccination
- •Body Mass Index >
- •Known bleeding disorders or receiving prescribed oral or parenteral anticoagulants.
- •Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study or could interfere with study evaluations.
结局指标
主要结局
Seroconversion rates to the 4 components of VAX2012Q
时间窗: Through day 21
Immune response to the vaccine will be measured in sera by the hemagglutination inhibition (HAI) assay.
次要结局
- Long term safety following vaccination assessed by Clinically significant AEs(After Day 21 through one year)
- C-reactive protein levels(Through day 7)
- Safety following vaccination assessed by Adverse events (AEs)(Through day 21)
- Immunogenicity of the two dose levels of VAX2012Q and of Fluzone Quadrivalent(Through day 21)
研究者
研究点 (7)
Loading locations...
相似试验
尚未招募
2 期
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgePoliomyelitisHaemophilus Influenzae Type B InfectionHepatitis BTetanusDiphtheriaPertussisNCT06618196LG Chem336
已完成
2 期
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT02833350Genentech, Inc.578
已完成
3 期
Efficacy and Safety of UI05MSP015CT in Functional DyspepsiaFunctional DyspepsiaNCT03225248Korea United Pharm. Inc.143
已完成
2 期
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerColorectal CancerNCT00109226Genentech, Inc.
已完成
2 期
Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)Moderate to Severe GoutHyperuricemiaNCT01109121Nuon Therapeutics, Inc.112